Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Raghavan

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
The Oncologist|July 19, 2018
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal TumorsAlberto Puccini, Heinz-Josef Lenz, John L Marshall, et al.
Molecular Cancer Research : MCR|March 11, 2018
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal CancersMohamed E Salem, Alberto Puccini, Axel Grothey, et al.
Cancer|July 21, 2021
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M Pye, et al.
Vaccine: X|April 6, 2023
COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patientsZainab Shahid, Alicia L Patrick, Michelle L Wallander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Urologic Oncology|June 6, 2022
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomesEarle F Burgess, J Alexa Sanders, Chad Livasy, et al.
JCO Precision Oncology|March 23, 2022
Landscape of <i>KRAS</i><sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated CancersMohamed E Salem, Sherif M El-Refai, Wei Sha, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyNicholas J Petrelli, Eric P Winer, Julie Brahmer, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
The Oncologist|July 19, 2018
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal TumorsAlberto Puccini, Heinz-Josef Lenz, John L Marshall, et al.
Molecular Cancer Research : MCR|March 11, 2018
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal CancersMohamed E Salem, Alberto Puccini, Axel Grothey, et al.
Cancer|July 21, 2021
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M Pye, et al.
Vaccine: X|April 6, 2023
COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patientsZainab Shahid, Alicia L Patrick, Michelle L Wallander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Urologic Oncology|June 6, 2022
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomesEarle F Burgess, J Alexa Sanders, Chad Livasy, et al.
JCO Precision Oncology|March 23, 2022
Landscape of <i>KRAS</i><sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated CancersMohamed E Salem, Sherif M El-Refai, Wei Sha, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyNicholas J Petrelli, Eric P Winer, Julie Brahmer, et al.
Pageof 13